Prime Medicine Reports Third Quarter 2026 Financial Results and Provides Business Updates
-- First patient dosed in global Phase 1/2 clinical trial of PM577a in Wilson disease, the first clinical study of an in vivo Prime Editing therapy from Prime Medicine; initial clinical data expected in 2027 -- -- Received FDA clearance of Investigational New Drug application for PM647 in Alpha-1 Antitrypsin Deficiency; initial clinical data expected in 2027 --
Covered in this story
Analyst targets on Prime Medicine Inc
- Citizens JMP: at $3.21 · target $7 by Oct 2027 · Market Outperform via Investing.com
“At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $PRME yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Prime Medicine Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.